Live Breaking News & Updates on Kalvista Pharmaceuticals|Page 3

Stay updated with breaking news from Kalvista pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

01.05.2024 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company’s investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment . Seite 1 ....

Ben Palleiko , Kalvista Pharmaceuticals Inc , Kalvista Pharmaceuticals , Chief Executive Officer , Kalvista Pharmaceuticals Chart , Alvista Pharmaceuticals Kurs , Alvista Pharmaceuticals Aktie ,

KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at Needham & Company LLC

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 191.67% from the stock’s […] ....

United States , Thomas Andrew Crockett , Benjaminl Palleiko , Kalvista Pharmaceuticals , Securities Exchange Commission , Needham Company , News Ratings For Kalvista Pharmaceuticals Daily , China Universal Asset Management Co , York Mellon Corp , Hedge Funds Weigh In On Kalvista Pharmaceuticals , Kalvista Pharmaceuticals Stock , Tower Research Capital , Kalvista Pharmaceuticals Inc , Get Free Report , Vista Pharmaceuticals , Andrew Crockett , Exchange Commission , Research Capital , New York Mellon Corp , Universal Asset Management , Kalvista Pharmaceuticals Daily , Nasdaq Kalv , Reiterated Rating , Needham Company Llc ,